dc.identifier.uri |
http://dx.doi.org/10.15488/3345 |
|
dc.identifier.uri |
http://www.repo.uni-hannover.de/handle/123456789/3375 |
|
dc.contributor.author |
Ludwig, K.
|
|
dc.contributor.author |
Schulenburg, Johann-Matthias Graf von der
|
|
dc.contributor.author |
Greiner, W.
|
|
dc.date.accessioned |
2018-05-23T06:37:52Z |
|
dc.date.available |
2018-05-23T06:37:52Z |
|
dc.date.issued |
2018 |
|
dc.identifier.citation |
Ludwig, K.; Graf von der Schulenburg, J.-M.; Greiner, W.: German Value Set for the EQ-5D-5L. In: PharmacoEconomics 2018 (2018), 1-12. DOI: https://doi.org/10.1007/s40273-018-0615-8 |
|
dc.description.abstract |
Objectives: The objective of this study was to develop a value set for EQ-5D-5L based on the societal preferences of the German population. As the first country to do so, the study design used the improved EQ-5D-5L valuation protocol 2.0 developed by the EuroQol Group, including a feedback module as internal validation and a quality control process that was missing in the first wave of EQ-5D-5L valuation studies. Methods: A representative sample of the general German population (n = 1158) was interviewed using a composite time trade-off and a discrete choice experiment under close quality control. Econometric modeling was used to estimate values for all 3125 possible health states described by EQ-5D-5L. The value set was based on a hybrid model including all available information from the composite time trade-off and discrete choice experiment valuations without any exclusions due to data issues. Results: The final German value set was constructed from a combination of a conditional logit model for the discrete choice experiment data and a censored at −1 Tobit model for the composite time trade-off data, correcting for heteroskedasticity. The value set had logically consistent parameter estimates (p < 0.001 for all coefficients). The predicted EQ-5D-5L index values ranged from −0.661 to 1. Conclusions: This study provided values for the health states of the German version of EQ-5D-5L representing the preferences of the German population. The study successfully employed for the first time worldwide the improved protocol 2.0. The value set enables the use of the EQ-5D-5L instrument in economic evaluations and in clinical studies. © 2018 The Author(s) |
eng |
dc.language.iso |
eng |
|
dc.publisher |
New York, NY : Springer International Publishing |
|
dc.relation.ispartofseries |
PharmacoEconomics 2018 (2018) |
|
dc.rights |
CC BY-NC 4.0 Unported |
|
dc.rights.uri |
https://creativecommons.org/licenses/by-nc/4.0/ |
|
dc.subject |
EQ-5D-5L |
eng |
dc.subject |
German population |
eng |
dc.subject |
EuroQol Group |
eng |
dc.subject |
health |
eng |
dc.subject.ddc |
610 | Medizin, Gesundheit
|
ger |
dc.title |
German Value Set for the EQ-5D-5L |
|
dc.type |
Article |
|
dc.type |
Text |
|
dc.relation.issn |
1170-7690 |
|
dc.relation.doi |
https://doi.org/10.1007/s40273-018-0615-8 |
|
dc.bibliographicCitation.volume |
2018 |
|
dc.bibliographicCitation.firstPage |
1 |
|
dc.bibliographicCitation.lastPage |
12 |
|
dc.description.version |
publishedVersion |
|
tib.accessRights |
frei zug�nglich |
|